Core Insights - Sanara MedTech's BIASURGE Advanced Surgical Solution has been awarded an Innovative Technology contract by Vizient, indicating its potential to improve healthcare outcomes and reduce costs in the surgical market [1][3][4] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare expenditures in the surgical market [7][8] - The company offers a range of surgical products, including BIASURGE, CellerateRX Surgical Activated Collagen Powder, and FORTIFY TRG Tissue Repair Graft, among others [8] Product Details - BIASURGE is a no-rinse irrigation solution designed for efficient surgical cleansing, featuring an antimicrobial preservative that provides broad-spectrum effectiveness against pathogenic microorganisms [5][6] - The product is optimized for pH, viscosity, and osmolality to ensure maximum performance while maintaining safety and effectiveness [5] - BIASURGE enhances surgical precision and visibility by maintaining a cleaner operative field, supporting infection-control strategies [6] Contract Significance - The Innovative Technology contract allows Vizient's extensive network of healthcare facilities to access BIASURGE at contracted pricing and pre-negotiated terms, effective January 1, 2026 [3][4] - The contract was awarded based on recommendations from hospital experts, highlighting BIASURGE's unique benefits over existing market products [3][4]

Core Insights - CorMedix Inc. announced that its product DefenCath has received an Innovative Technology designation from Vizient, indicating its potential impact on patient care and healthcare operations [1][4] - DefenCath is the first FDA-approved antimicrobial catheter lock solution in the U.S., specifically designed to reduce catheter-related bloodstream infections in adult patients undergoing chronic hemodialysis [3][5] - In clinical studies, DefenCath demonstrated a 71% reduction in the risk of developing catheter-related bloodstream infections compared to control [3] Company Overview - CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening conditions, including DefenCath for preventing catheter-related bloodstream infections [5] - Following the acquisition of Melinta Therapeutics LLC in August 2025, CorMedix is also commercializing a portfolio of anti-infective products [5] - The company has ongoing clinical studies for DefenCath in various patient populations and intends to expand its applications [6] Industry Context - Vizient, the organization granting the Innovative Technology designation, represents a diverse client base with approximately $156 billion in annual purchasing volume, including academic medical centers and community hospitals [4] - The Innovative Technology designation is awarded based on evaluations by healthcare experts for products that enhance clinical care and improve business operations [2]